Prostate Cancer Update

View Top 200 Chart

Back to Rankings Page

Health & Fitness
**Prostate Cancer Update**

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.

Latest Episodes:

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal Oct 03, 2026

Show notes

Featuring an interview with Dr Neeraj Agarwal, including the following topics:

Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)
Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)
Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)
Managing treatment-related adverse events from capivasertib (20:08)
Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)
Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 8 Sep 16, 2026

Show notes

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)
Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)
Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)
Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 7 Sep 16, 2026

Show notes

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)
Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)
Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)
Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)
Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)

CME information and select publications

Prostate Cancer — The Optimal Use of Hormonal Therapy Sep 08, 2026

Show notes

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:

Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)
Nonmetastatic Disease (10:32)
Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)

CME information and select publications

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Sep 05, 2026

Show notes

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)

CME information and select publications

For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress Aug 31, 2026

Show notes

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:

Introduction (0:00)
Overview of Prostate Cancer (3:00)
Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
Potential Role of Capivasertib in Metastatic HSPC (27:22)
Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 27, 2026

Show notes

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00)
Case: A man with muscle-invasive bladder cancer who receives neoadjuvant chemotherapy with durvalumab receives positive circulating tumor DNA results before cystectomy and negative results after surgery (7:41)

CME information and select publications

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 26, 2026

Show notes

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

Case: A man in his early 80s with non-muscle-invasive bladder cancer (NMIBC) monitored by repeat TURBTs develops localized muscle-invasive bladder cancer and enrolls in a clinical trial of neoadjuvant enfortumab vedotin with pembrolizumab (0:00)
Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (CIS) receives BCG induction and experiences relapse of CIS during BCG maintenance (9:24)

CME information and select publications

AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 22, 2026

Show notes

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29)

CME information and select publications

AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 21, 2026

Show notes

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected